GlassScriptPhysician profile
Mary B Hensley
NPI 1134206642
$4,359.70
in general payments reported to CMS, 2019-2025
47 companies · $1,191 in 2025
The $1,191 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $639 · 2020: $71.55 · 2021: $103 · 2022: $365 · 2023: $1,005 · 2024: $985 · 2025: $1,191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,180.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $550.69 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $478.53 | 2022-2025 | |
| Pfizer INC. | $395.53 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $277.55 | 2019-2024 | Qelbree |
| Glaxosmithkline, LLC. | $272.99 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Insulet Corporation | $201.96 | 2022-2024 | Omnipod |
| Lilly USA, LLC | $170.99 | 2020-2025 | Mounjaro, Zepbound, Emgality |
| Otsuka America Pharmaceutical, INC. | $141.92 | 2019-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $114.57 | 2019-2025 | |
| Lundbeck LLC | $112.23 | 2022-2025 | Rexulti, Vyepti |
| Astellas Pharma US INC | $111.80 | 2019-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.41 | 2019-2025 | Tradjenta, Jardiance |
| Corcept Therapeutics | $98.26 | 2020-2025 | Korlym |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $97.95 | 2023-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $96.54 | 2019-2025 | Gattex, Trintellix |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $89.03 | 2019-2025 | Fanapt |
| Exact Sciences Corporation | $79.44 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $70.35 | 2019-2025 | Farxiga |
| Medtronic, INC. | $69.95 | 2023-2024 | Minimed 780g, Intellis Adaptivestim |
| Xeris Pharmaceuticals, INC. | $55.55 | 2023-2024 | Gvoke Hypopen |
| Amgen INC. | $53.13 | 2021-2025 | Repatha, Otezla, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.60 | 2019-2024 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $51.33 | 2024-2025 | Voquezna |
| Kvk-Tech, INC. | $50.89 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $47.12 | 2019-2025 | Uzedy |
| Harmony Biosciences LLC | $44.30 | 2025 | |
| Amneal Pharmaceuticals LLC | $42.89 | 2022-2023 | Unithroid |
| E.R. Squibb & Sons, L.L.C. | $38.76 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.53 | 2022-2023 | |
| Tandem Diabetes Care, INC. | $33.20 | 2023-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbott Laboratories | $31.47 | 2021-2025 | Freestyle Libre 3 |
| Neurocrine Biosciences, INC. | $31.27 | 2025 | |
| Axsome Therapeutics, INC. | $30.79 | 2023 | Auvelity |
| Merck Sharp & Dohme LLC | $28.80 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Sanofi Pasteur INC. | $25.85 | 2019-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.47 | 2022 | |
| Collegium Pharmaceutical, INC. | $20.10 | 2025 | Jornay Pm |
| Shield Therapeutics INC | $17.66 | 2024 | |
| Almatica Pharma LLC | $16.72 | 2023 | Loreev Xr |
| Corium, LLC | $16.64 | 2025 | Azstarys |
| Jazz Pharmaceuticals INC. | $15.29 | 2019 | |
| Antares Pharma, INC. | $14.32 | 2023 | Nocdurna, Xyosted, Tlando |
| Avanir Pharmaceuticals, INC. | $12.66 | 2019 | |
| Mycovia Pharmaceuticals, INC. | $12.11 | 2022 | |
| Daiichi Sankyo INC. | $10.93 | 2019 | |
| Vertical Pharmaceuticals, LLC | $10.83 | 2019 | |
| Organon LLC | $5.80 | 2023 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Hensley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.